## Streptococcus species abundance in the gut is linked to subclinical coronary atherosclerosis in 8973 participants from the SCAPIS cohort

- 4
- 5 Sergi Sayols-Baixeras, PhD<sup>1,2\*</sup>, Koen F. Dekkers, MSc<sup>1\*</sup>, Gabriel Baldanzi, MD<sup>1</sup>, Daniel
- 6 Jönsson, DDS, PhD<sup>3,4,5</sup>, Ulf Hammar, BSc<sup>1</sup>, Yi-Ting Lin, MD, PhD<sup>1,6</sup>, Shafqat Ahmad,
- 7 PhD<sup>1,7</sup>, Diem Nguyen, PhD<sup>1</sup>, Georgios Varotsis, DVM<sup>1</sup>, Sara Pita, MSc<sup>8,9</sup>, Nynne Nielsen,
- 8 MSc<sup>8</sup>, Aron C. Eklund, PhD<sup>8</sup>, Jacob B. Holm, PhD<sup>8</sup>, H. Bjørn Nielsen, PhD<sup>8</sup>, Ulrika Ericson,
- 9 PhD<sup>3</sup>, Louise Brunkwall, PhD<sup>3,10</sup>, Filip Ottosson, PhD<sup>3,11</sup>, Anna Larsson, MD<sup>3</sup>, Dan Ericson,
- 10 DDS, PhD<sup>12</sup>, Björn Klinge, DDS, PhD<sup>5,13</sup>, Peter M. Nilsson, MD, PhD<sup>3,14</sup>, Andrei
- 11 Malinovschi, MD, PhD<sup>15</sup>, Lars Lind, MD, PhD<sup>16</sup>, Göran Bergström, MD, PhD<sup>17,18</sup>, Johan
- 12 Sundström, MD, PhD<sup>16,19</sup>, Johan Ärnlöv, MD, PhD<sup>6,20</sup>, Gunnar Engström, MD, PhD<sup>3</sup>, J.
- 13 Gustav Smith, MD, PhD<sup>21,22,23</sup>, Marju Orho-Melander, PhD<sup>3†</sup>and Tove Fall, DVM, PhD<sup>1†</sup>
- 14 \*Shared first authorship
- 15 <sup>†</sup>Shared senior authorship
- 16
- <sup>1</sup>Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory,
- 18 Uppsala University, Uppsala, Sweden
- 19 <sup>2</sup>CIBER Cardiovascular diseases (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain
- <sup>3</sup>Department of Clinical Sciences in Malmö, Lund University, Malmö, Sweden
- <sup>4</sup>Public Dental Service of Skåne, Lund, Sweden
- <sup>5</sup>Department of Periodontology, Faculty of Odontology, Malmö University, Malmö, Sweden
- <sup>6</sup>Division of Family Medicine and Primary Care, Department of Neurobiology, Care Science
- 24 and Society, Karolinska Institutet, Huddinge, Sweden
- <sup>25</sup> <sup>7</sup>Preventive Medicine Division, Harvard Medical School, Brigham and Women's Hospital,

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. Boston, MA, United States of America

- 27 <sup>8</sup>Clinical Microbiomics A/S, Copenhagen, Denmark
- <sup>9</sup>The Novo Nordisk Foundation Center for Biosustainability, Technical University of
- 29 Denmark, Lyngby, Denmark
- 30 <sup>10</sup>Clinical Studies Sweden, Forum Söder, Region Skåne, Lund, Sweden
- <sup>31</sup> <sup>11</sup>Section for Clinical Mass Spectrometry, Danish Center for Neonatal Screening, Department
- 32 of Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark
- <sup>12</sup>Department of Cariology, Faculty of Odontology, Malmö University, Malmö, Sweden
- <sup>13</sup>Department of Dental Medicine, Karolinska Institutet, Solna, Sweden
- <sup>14</sup>Department of Internal Medicine, Skånes University Hospital, Malmö, Sweden
- <sup>15</sup>Department of Medical Sciences, Clinical Physiology, Uppsala University, Uppsala,
- 37 Sweden
- <sup>16</sup>Department of Medical Sciences, Clinical Epidemiology, Uppsala University, Uppsala,

39 Sweden

- 40 <sup>17</sup>Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska
- 41 Academy, University of Gothenburg, Gothenburg, Sweden
- 42 <sup>18</sup>Department of Clinical Physiology, Sahlgrenska University Hospital, Region Västra
- 43 Götaland, Gothenburg, Sweden
- <sup>19</sup>The George Institute for Global Health, University of New South Wales, Sydney, Australia
- 45 <sup>20</sup>School of Health and Social Studies, Dalarna University, Falun, Sweden

- 46 <sup>21</sup>The Wallenberg Laboratory/Department of Molecular and Clinical Medicine, Institute of
- 47 Medicine, Gothenburg University and the Department of Cardiology, Sahlgrenska University
- 48 Hospital, Gothenburg, Sweden
- 49 <sup>22</sup>Department of Cardiology, Clinical Sciences, Lund University and Skåne University
- 50 Hospital, Lund, Sweden
- <sup>23</sup>Wallenberg Center for Molecular Medicine and Lund University Diabetes Center, Lund
- 52 University, Lund, Sweden
- 53 Short title: Gut streptococci are linked to atherosclerosis
- 54 Correspondence to: Tove Fall, PhD, Professor in Molecular Epidemiology
- 55 Department of Medical Sciences, Molecular Epidemiology
- 56 Uppsala University, EpiHubben, MTC-huset
- 57 75185, Uppsala, Sweden.
- 58 E-mail: tove.fall@medsci.uu.se
- 59 Word Count
- 60 Abstract: 346
- 61 Main text: 4951

#### 62 ABSTRACT

63 **BACKGROUND:** Gut microbiota have been implicated in atherosclerotic disease, but their 64 relation with subclinical coronary atherosclerosis is unclear. This study aimed to identify 65 associations between the gut microbiome and computed tomography-based measures of 66 coronary atherosclerosis, and to explore relevant clinical correlates.

METHODS: We conducted a cross-sectional study of 8973 participants aged 50 to 65 without 67 overt atherosclerotic disease from the population-based Swedish Cardiopulmonary BioImage 68 Study (SCAPIS). Coronary atherosclerosis was measured using coronary artery calcium score 69 (CACS) and coronary computed tomography angiography (CCTA). Gut microbiota species 70 71 abundance and functional potential were assessed with shotgun metagenomics sequencing of 72 stool samples, and their association with coronary atherosclerosis was evaluated with multivariable regression models adjusted for cardiovascular risk factors. Associated species 73 were evaluated for association with inflammatory markers, metabolites, and corresponding 74 75 species in saliva.

76 **RESULTS:** The mean age of the study sample was 57.4 years, and 53.7% were female. Coronary artery calcification was detected in 40.3% of participants, and 5.4% had at least one 77 stenosis with more than 50% occlusion. Sixty-four species were associated with CACS 78 independent of cardiovascular risk factors, with the strongest associations observed for 79 Streptococcus anginosus and S. oralis subsp. oralis ( $P < 1 \times 10^{-5}$ ). Associations were largely 80 similar across CCTA-based measurements. Out of the 64 species, 19 species, including 81 streptococci and other species commonly found in the oral cavity, were associated with high-82 sensitivity C-reactive protein plasma concentrations and 16 with neutrophil counts. Oral 83 84 species in the gut were negatively associated with plasma indole propionate and positively associated with plasma secondary bile acids and imidazole propionate. Five species correlated 85 with the same species in saliva and were associated with worse dental health in the Malmö 86 Offspring Dental Study. Microbial functional potential of dissimilatory nitrate reduction, 87 anaerobic fatty acid beta-oxidation and amino acid degradation was associated with CACS. 88

89 CONCLUSIONS: This study provides evidence of an association of a gut microbiota 90 composition characterized by increased abundance of *Streptococcus* spp. and other species 91 commonly found in the oral cavity with coronary atherosclerosis and systemic inflammation. 92 Further longitudinal and experimental studies are warranted to explore the potential implication 93 of a bacterial component in atherogenesis.

- 94 Key Words: Atherosclerosis, coronary artery calcium score, tomography, metagenomics, gut
- 95 microbiota, *Streptococcus*.

96		CLINICAL PERSPECTIVE
97		WHAT IS NEW?
98	٠	Shotgun metagenomics identified associations between gut species and subclinical
99		atherosclerosis assessed with computed tomography-derived coronary artery calcium score
100		(CACS) in 8973 participants, with an overrepresentation of the Streptococcus and
101		Oscillobacter genera.
102	•	The relative abundance of CACS-associated oral species detected in fecal samples was
103		negatively associated with indole propionate, while positively associated with secondary
104		bile acids and imidazole propionate.
105	•	Gut Streptococcus spp. were positively associated with circulating biomarkers of systemic
106		inflammation and infection response, and with the same species located in the mouth, which
107		were in turn associated with oral pathologies.
108		WHAT ARE THE CLINICAL IMPLICATIONS?
109	•	We describe the link between gut microbiota composition, especially species commonly
110		found in the mouth, with subclinical coronary atherosclerosis and biomarkers of
111		inflammation in the largest cardiovascular and metagenomics study to date.
112	•	The effects of gut and oral Streptococcus spp. on risk for coronary artery disease merit
113		further longitudinal and experimental studies.

#### 114 Non-standard Abbreviation and Acronyms

115	CACS	Coronary artery calcium score
116	CCTA	Coronary computed tomography angiography
117	CVD	Cardiovascular disease
118	GMM	Gut metabolic module
119	hsCRP	High-sensitivity C-reactive protein
120	ln	Natural logarithm
121	MGS	Metagenomics species
122	MODS	Malmö Offspring Dental Study
123	MOS	Malmö Offspring Study
124	SCAPIS	Swedish CArdioPulmonary bioImage Study
125	SIS	Segment involvement score
126	VGS	Viridans streptococci group

Atherosclerotic cardiovascular disease (CVD) is a major cause of death and disability.<sup>1</sup> The 127 microbial community of the gastrointestinal tract, also known as the gut microbiota, is 128 hypothesized to affect the progression of atherosclerosis through three potential mechanisms. 129 Firstly, microbial metabolites can interfere with the host metabolism, including lipid 130 metabolism.<sup>2</sup> The composition of the gut microbiota has been linked to metabolic disorders 131 such as obesity, insulin resistance and type 2 diabetes, although the causal relation and direction 132 are unclear.<sup>3</sup> Secondly, translocation of live bacteria or bacterial structural components (e.g., 133 endotoxins) into the bloodstream can contribute to low-grade systemic inflammation, thereby 134 exacerbating the atherosclerosis process.<sup>2</sup> Thirdly, the discovery of bacteria within 135 atherosclerotic plaques has led to the proposal that bacteria might directly infect plaques and 136 accelerate atherosclerosis progression. <sup>4</sup> Case-control studies of symptomatic coronary 137 atherosclerotic disease have identified differences in the abundance of more than 500 gut 138 species. 5-7 However, dissimilarities in medical treatment and lifestyle factors in cases and 139 controls make these studies prone to bias. Thus, studies of individuals without overt coronary 140 disease in large population-based samples incorporating biomarkers of metabolism and 141 inflammation are warranted. 142

Recent evidence supports that oral species are commonly transmitted to the gut, <sup>8</sup> indicating 143 that the gut and oral microbiota are connected rather than being two separate microbial 144 communities. Causative species of dental caries, plaque-dwelling bacteria and endocarditis-145 associated species including species from the viridans streptococci group (VGS) are reported 146 to be transmitted at a high rate. Additionally, an overlap is reported between oral bacteria such 147 as Veillonella spp. and Streptococcus spp. found in oral cavity, fecal samples and carotid 148 atherosclerotic plaque. <sup>9</sup> Given the association between dental health and endothelial 149 dysfunction and atherosclerotic disease, <sup>10-12</sup> the gut may serve as a niche and/or entry route for 150

oral pathogenic bacteria passing to the blood. However, there is a lack of studies assessing the
association of atherosclerosis-related gut species with the oral microbiome.

To avoid the limitations of previous studies and gain insight into the relation of the gut microbiota and atherosclerosis, we sought to identify associations between the gut microbiome and computed tomography-based measures of subclinical coronary atherosclerosis in a large cohort of middle-aged participants from the Swedish CArdioPulmonary bioImage Study (SCAPIS). We further assessed associations between atherosclerosis-associated gut bacterial species and biomarkers of inflammation and infection, plasma metabolites, and the abundance of corresponding bacterial species in the oral cavity.

#### 160 **METHODS**

#### 161 Data Availability

De-identified metagenomic sequencing data can be accessed from the ENA under accession number PRJEB51353 (https://www.ebi.ac.uk/ena/browser/view/prjeb51353). Access to the pseudonymized data requires ethical approval from the Swedish Ethical Review Board and approval from the SCAPIS Data access board (https://www.scapis.org/data-access/). The source code and the summary data underlying all figures used to generate the results for the analysis are available at https://github.com/MolEpicUU/GUTSY CACS.

#### 168 Study Design and Participants

The study design is illustrated in **Figure 1**. The primary data source was SCAPIS, a populationbased study focusing on cardiovascular and respiratory disease in 30154 subjects 50–64 years of age from six sites in Sweden. <sup>13</sup> Fecal metagenomics data was available for 4839 participants from Uppsala and 4980 from Malmö after removal of 10 samples for failing in the quality control. After excluding subjects with missing information on country of birth (n=39), coronary artery calcium score (CACS) (n=356) or who had self-reported CVD (n=451) including

atherosclerotic CVD (n=119), 4541 participants from Uppsala and 4432 from Malmö
remained.

The association between gut species and their counterparts in saliva samples and with oral health was investigated in participants of the Malmö Offspring Dental Study (MODS, n=831, mean age 52.9 years), a substudy of the family-based Malmö Offspring Study (MOS). <sup>10,14</sup> Salivary metagenomics, oral examination data, and complete data on age and sex were available for 650 subjects; informative fecal metagenomics data from MOS were available for 435 of those subjects.

All participants gave written informed consent. The study was conducted in accordance with the Declaration of Helsinki and was approved by the regional ethics committees (SCAPIS: Dnr 2010-228-31M and Dnr 2018/315; MODS: Dnr 2013/761; and MOS: Dnr 2012/594).

#### 186 Atherosclerosis Measurements

Cardiac imaging in SCAPIS included coronary computed tomography angiography (CCTA) as 187 188 described previously.<sup>15</sup> Briefly, computed tomography was performed with a dedicated dualsource scanner and a Stellar Detector (Somatom Definition Flash, Siemens Medical Solutions). 189 Non-contrast images for calcium scoring were obtained from all subjects, followed by contrast-190 enhanced images from subjects without contraindications. CACS was determined using the 191 syngo.via calcium scoring software (Volume Wizard; Siemens). The area of calcification was 192 summed for the whole coronary artery tree to a CACS according to Agatston.<sup>16</sup> Radiologists 193 inspected the images for any coronary atherosclerosis, segment involvement score (SIS), Duke 194 prognostic coronary artery disease index modified for SCAPIS, <sup>15</sup> and occlusive atherosclerosis 195 196 (≥50% stenosis in at least one vessel) (see **Supplemental Methods**). We included individuals with valid readings in at least four proximal segments. Carotid atherosclerosis was categorized 197 as absent, unilateral, or bilateral<sup>13</sup> from two-dimensional gray-scale ultrasound images obtained 198

with a Siemens Acuson S2000 ultrasound scanner and a 9L4 linear transducer (both from
Siemens, Germany) using a standardized protocol and the Mannheim consensus.<sup>17</sup>

#### 201 Metagenomics

DNA was extracted from fecal samples (SCAPIS and MOS) and saliva samples (MODS) at 202 Clinical Microbiomics (Copenhagen, Denmark). The analytical pipeline is described in detail 203 in Supplemental Methods. In brief, libraries of fragmented DNA were sequenced with the 204 Illumina Novaseq 6000 platform. This technique generated an average of 26.3 million read 205 pairs per sample in SCAPIS-Malmö and MOS, 25.3 million read pairs in SCAPIS-Uppsala, 206 and 26.3 million read pairs in MODS. Non-host reads and data from these and other cohorts 207 were used to build separate nonredundant gene catalogues for fecal and saliva samples. 208 Metagenomic species and corresponding signature gene were identified.<sup>18</sup> In all three datasets, 209 species abundance was estimated by mapping reads to the signature gene sets and 210 normalization for effective gene length. The taxonomic information for the two catalogues was 211 mapped with the NCBI RefSeq database.<sup>19</sup> 212

Alpha (Shannon diversity index, inverse Simpson index, and Chao1) and beta diversity 213 (Bray-Curtis dissimilarity) were estimated with the R v4.1.1 package vegan v2.5-7 using 214 rarefied data.<sup>20</sup> Rarefied data were also used to define individuals with above/less than median 215 abundance of each species. The functional potential profile of the gut microbiota was 216 determined by assigning genes to gut metabolic modules (GMM),<sup>20</sup> which includes 103 217 metabolic pathways that represent cellular enzymatic processes. The GMM abundance was 218 estimated using the Omixer-RPM v0.3.226 R package, with a minimum module coverage 219 220 threshold set at 66.6%. Before conducting statistical analysis, the abundance data for each species in all analytical datasets and for each GMM were transformed with the formula ln(x+1), 221 222 where x denotes the relative abundance of each species or GMM, followed by z-transformation 223 to set the mean to 0 and SD to 1.

#### 224 Clinical Chemistry, Hematology and Metabolomics

Venous plasma samples were analyzed for high-density lipoprotein (HDL) and low-density
lipoprotein (LDL) cholesterol, triglycerides, and high-sensitivity C-reactive protein (hsCRP).
Blood cells were counted by standard methods. CACS-associated species-plasma metabolite
associations in SCAPIS with q-value <0.05 were accessed from the GUTSY atlas</li>
(https://gutsyatlas.serve.scilifelab.se/) from Dekkers et al.<sup>21</sup>

#### 230 Oral Health Phenotypes

Dental examinations of MODS participants were done by five dentists. Both surfaces with caries and fillings were recorded on all teeth, counting four to five surfaces per tooth. Surfaces with caries were detected using standard clinical criteria aided by mirror, probe (Hu-Friedy EXD57), and bite-wing radiographs combining initial and manifest lesions. Filled surfaces included both fillings and crowns. Gingival inflammation was recorded as percentage of bleeding on probing, excluding wisdom teeth, and counting six surfaces per tooth.

#### 237 Other Phenotypes

In SCAPIS and MOS, data on country of birth, smoking, physical activity, and diet were collected with validated standardized questionnaires. Blood pressure and body mass index (BMI) were recorded. Data on medications were acquired from the drug prescription register, self-report, plasma measurements, and other sources. Relatedness in SCAPIS was based on kinship analysis of genotype data, assigning first-degree relatives individuals to the same family, and relatedness in MODS/MOS was based on family information from the study design phase. Collected phenotypes are described in detail in **Supplemental Methods**.

#### 245 Statistical Analysis

Association between Gut Microbiota Diversity and Atherosclerosis The association of alpha
diversity with coronary atherosclerosis was assessed by linear mixed models with ln(CACS+1)

as the dependent and alpha diversity indices as the independent variables. To address the 248 potential influence of family relatedness, the first degree-relatedness among 423 participants 249 from 208 families was accounted for with a random effect variable by using the *lmerTest* v3.1-250 3 R package. Furthermore, two sets of covariates were modeled as fixed effects. The basic 251 model was adjusted for age, sex, country of birth, study center, and metagenomics extraction 252 plate. The main model was further adjusted for smoking; physical activity; energy-adjusted 253 254 carbohydrate, protein, and fiber intake; systolic and diastolic blood pressure; total cholesterol; high- and low-density lipoprotein cholesterol; ln(triglycerides); diabetes; BMI; and self-255 256 reported medication for dyslipidemia, hypertension, and diabetes. Correlation of covariates and alpha diversity measurements are reported in Figure S1. 257

Beta diversity was assessed by a distance-based multivariate analysis of variance of ln(CACS+1) as the independent variable using the *dmanova* function in the *GUniFrac* v1.3 package. These analyses were adjusted for the same two set of covariates as used in the alpha diversity analyses. However, in contrast to the alpha diversity analyses, only one participant from each family cluster was included, rather than by treating family relatedness as a random effect variable.

Association of Species and Bacterial Functions with CACS. Extensive simulations were 264 conducted before the analysis and supported the use of linear regression to minimize false-265 positive findings (Supplemental Methods, Figure S2). Hence, a series of linear mixed 266 multivariable regressions were performed with the ln(CACS+1) as the dependent variable and 267 the abundance of each species and GMM as the independent variable. The models were fitted 268 269 for each species and each GMM separately; covariates from the basic model were used as fixed effects and family relatedness as random effects. Multiple testing was accounted for using the 270 Benjamini-Hochberg False Discovery Rate (FDR) at 5%.<sup>22</sup> A Taxon Set Enrichment Analysis<sup>23</sup> 271

based on the fgsea v1.18.0 R package based on P value ranking separately for positive and 272 negative regression coefficients was used to determine whether certain genera were enriched. 273 Species with a q-value <0.05 in the basic model were assessed adjusting for main model 274 covariates, again accounting for multiple testing. To determine whether associations were 275 caused by influential observations, unscaled dfbeta values were calculated using the *influence* 276 and dfbetas R functions. The linear regression estimates were deemed unreliable if the 277 278 exclusion of the observations with highest absolute dfbeta value resulted in a change of the direction of the regression coefficient or in a  $P \ge 0.05$ . Findings not caused by an influential 279 280 observation are referred to as "CACS-associated species". Effect estimate modification by sex was assessed for CACS-associated species by entering an interaction term between sex and 281 each of the fixed effect variables in the model and extracting the interaction coefficient of sex 282 with species. 283

Sensitivity Analyses. In three separate analyses, we excluded three groups of participants: those 284 285 in whom proton-pump inhibitors were measured in plasma, those with inflammatory bowel disease, and those treated with antibiotics during the year before the baseline visit. 286 Furthermore, the analyses for CACS-associated species were repeated with the Shannon 287 diversity index as a covariate to test if findings were driven by global changes in the gut 288 microbiota composition rather than change in individual species. Lastly, the associations from 289 the main model were tested in an ordinal mixed model using CACS categories as the outcome 290 (CACS: 0; 1-100; 101-400; >400) using Stata v15. 291

Association between CACS-Associated Species and CCTA-Based Measurements and Carotid Plaques. We assessed the association of CACS-associated species with presence of any coronary atherosclerotic plaque or coronary stenosis >50% in at least one vessel in a series of logistic mixed regressions. The association between CACS-associated species and SIS,

modified Duke index, and number of carotid vessels with atherosclerosis plaques were assessed
with ordinal mixed regression models. Categories 4, 5 and 6 of the modified Duke index were
merged due to low number of observations. The logistic and ordinal mixed models were fitted
using Stata v15 and were adjusted for the main model covariates.

300 *Clustering of Plasma Metabolites associated with CACS-Associated Species*. For each CACS-301 associated species, the three strongest associations with plasma metabolites were selected 302 based on their p-value. For the resulting unique subset of 63 metabolites hierarchical clustering 303 was performed based on the Euclidian distance on the partial Spearman correlation coefficients.

Associations between CACS-Associated Species and Markers of Systemic Inflammation and Infection. A series of linear mixed models was fitted to assess the association between CACSassociated species (independent variable) and ln-transformed hsCRP, and ln-transformed counts of neutrophils and leukocytes, separately, as the dependent variable. The models were adjusted for the same covariates as the main model.

Associations between Gut and Oral CACS-Associated Species and between Oral CACS-309 Associated Species and Oral Health Phenotypes. To investigate the association between 310 CACS-associated species in the gut and the corresponding species in saliva, MOS/MODS data 311 was analyzed with a series of partial Spearman correlations from a mixed model based on rank-312 transformed data (details in Supplemental Methods). The models were adjusted for age, sex, 313 and metagenomics extraction plate as fixed effects and family relatedness as a random effect. 314 The oral species associated (q-value <0.05) with the corresponding CACS-associated gut 315 species were assessed for association with three oral health phenotypes: filled surfaces (split 316 by deciles in 10 categories), caries, and gingival inflammation. Filled surfaces and caries were 317 assessed using ordinal mixed regressions using the Ordinal v2019.12-10 R package, while 318 319 gingival inflammation was assessed with a linear mixed model. These regression models were

- 320 adjusted for age, sex, smoking, education, Silness-Löe plaque index, as a marker of oral
- 321 hygiene, and the activity in the hour immediately before the dental examination (e.g., eating,
- 322 brushing teeth, smoking) as fixed effects and family relatedness as a random effect.

#### 323 **RESULTS**

Gut Microbiota Composition and Richness Are Associated with Subclinical 324 Atherosclerosis and Attenuated by Adjustment for Lifestyle Factors, Diet and Medication 325 The study included 8973 subjects with no self-reported history of CVD. Among them, 40.3% 326 had measurable coronary artery calcification and 5.4% manifested at least one stenosis with 327 >50% occlusion (Table 1, Table S1). The Shannon diversity index—a measure of overall 328 329 species richness and evenness within each sample—was inversely associated with CACS (n=8972,  $\beta$ =-0.17, P=5.1×10<sup>-4</sup>) in the basic model. The basic model was adjusted for age, sex, 330 331 country of birth, and technical variables as fixed effects, and family relatedness as a random effect. However, the association was attenuated and non-significant in the main model with 332 more extensive adjustment (n=8118,  $\beta$ =-0.03, P=0.53). The covariates primarily attenuating 333 the association were triglycerides and BMI, followed by medication, blood pressure traits, 334 smoking, HDL cholesterol, and physical activity (Figure S3). Alternative alpha diversity 335 indices were similarly associated with CACS (Figure 2a). Beta diversity—a measure of the 336 amount of variation in species composition-differed among CACS values in both models, 337 although the main model was attenuated ( $r_{\text{basic}}^2=0.0005$ ;  $P_{\text{basic}}=2\times10^{-25}$  vs  $r_{\text{main}}^2=0.0002$ ; 338  $P_{\text{main}}=0.009$ ) mainly by the same covariates that attenuated the relationship between alpha 339 diversity and CACS (Figure 2b, Figure S3). These models were not adjusted for family 340 relatedness, but only one of the participants in each family cluster was included instead (n<sub>basic</sub>= 341 342 8757,  $n_{main} = 7921$ ). These findings encouraged us to investigate species-specific associations.

## 343 Species Associated with Subclinical Atherosclerosis Are Enriched in Species from 344 Streptococcus and Oscillibacter Genera

The taxonomic profiling of fecal samples identified the prevalence of 1985 species, with 411 species having a prevalence <1%. The average number of species per sample was 325, with a range of 11 to 696. The dominant phyla were Firmicutes (72%) and Bacteroidetes (20%)

(Figure 3). In the basic model, including 8973 individuals, the relative abundance of 78 species (73 of which had a prevalence  $\geq 1\%$ ) showed a positive association with CACS, while 29 species (all of which had a prevalence  $\geq 1\%$ ) were negatively associated. (Table S2). Taxonset enrichment analysis revealed an overrepresentation of the *Streptococcus* and *Oscillibacter* genera in the positive CACS associations (Table S3).

## 353 Sixty-four Species Were Associated with CACS Independent of Cardiovascular Risk 354 Factors

In the main model, which included 8118 individuals with complete data on covariates, 67 355 species remained associated with CACS (54 positively and 13 negatively) (Figure 4). 356 Covariates included age, sex, country of birth, metagenomics extraction plate, smoking, 357 physical activity, energy-adjusted carbohydrate, protein, fiber intake, blood pressure, lipids, 358 diabetes, BMI, self-reported cardiovascular medication, and family relatedness. However, the 359 associations of Peptoniphilus harei, Muribaculaceae sp. (MGS identifier: HG3A.1967) and 360 361 Eubacteriales sp. (HG3A.0270) were deemed non-robust, as the removal of single influential observations abolished the association (Table S4). Among the remaining 64 CACS-associated 362 species, 51 had a positive association with CACS, while 13 had negative associations (Figure 363 4, Figure 5). The abundance of bacteria across CACS groups and the previously excluded 364 SCAPIS participants with self-reported atherosclerotic CVD is shown in Figure S4. The lowest 365 P values were observed for Streptococcus anginosus, S. oralis subsp. oralis, Escherichia coli, 366 Eubacteriales sp. (HG3A.1354) and Intestinimonas sp. (HG3A.1149), all positively associated 367 with CACS. Other associated species included S. parasanguinis, S. gordonii, and 368 369 S. agalactiae. Comparison of the main clinical characteristics in participants with high and low abundance of CACS-associated species (cut-off median) showed that those with higher 370 abundance of the two most strongly associated species, S. anginosus, and S. oralis subsp. oralis 371 372 had in general more cardiovascular risk factors (Table S5). Furthermore, there were indications

that the associations between *S. agalactiae*, *Rothia mucilaginosa*, two *Eubacteriales* spp. (HG3A.0511 and HG3A.0854), and an *Oscillibacter* sp. (HG3A.0243) and CACS were modified by sex (interaction P < 0.05, **Table S4**). After adjusting for multiple testing the associations were no longer significant.

#### 377 Sensitivity Analyses

The exclusion of individuals who used proton-pump inhibitors, had inflammatory bowel disease, or were treated with antibiotics in the previous 12 months before the baseline visit, as well as adjusting for Shannon diversity index showed largely similar effect estimates as the main model (**Figure S5**). Applying ordinal mixed models showed consistent effect direction and P<0.05 for 61 out of 64 species (**Table S4**). Overall, these findings indicate that the associations identified in the main analysis were reliable.

# Gut Metabolic Modules Related to Dissimilatory Nitrate Reduction, Anaerobic Fatty Acid Beta-oxidation and Amino Acid Degradation are Positively Associated with Subclinical Atherosclerosis.

In the basic model (n = 8973), 36 GMMs were positively associated while 4 had a negative association with CACS (**Table S6**). In the main model (n=8118), 11 GMMs were found to be positively associated with CACS, and none were negatively associated with CACS (**Table S7**). None of these associations were driven by an influential observation. These 11 GMMs are involved in various metabolic pathways, including amino acid degradation (e.g., asparagine, proline, and valine degradation), anaerobic fatty acid beta-oxidation, enzymatic reactions on lactate consumption, propionate production, and nitrogen metabolism.

#### **394 Other Atherosclerosis Measurements**

Next, we assessed the association between CACS-associated species and four CCTA
 measurements (presence of coronary atherosclerosis plaque, coronary stenosis >50%, modified

<sup>397</sup> Duke index, and SIS) and the number of carotid vessels with atherosclerotic plaque adjusted <sup>398</sup> for the covariates in the main model. Twenty-five CACS-associated species were also <sup>399</sup> associated with any coronary atherosclerotic plaque, 5 with coronary stenosis >50%, 39 with <sup>400</sup> the modified Duke index, 44 with the SIS, and 5 with carotid plaque (*P*<0.05), all in the same <sup>401</sup> direction as with CACS (**Figure 5**). The correlation among atherosclerosis measurements is <sup>402</sup> shown in **Figure S6**.

## 403 CACS-Associated Species are Linked to Numerous Plasma Metabolites and Clustered 404 into Distinct Groups Based on their Strongest Associations

We assessed whether the 60 CACS-associated species available in the GUTSY Atlas<sup>21</sup> 405 describing species-metabolite associations were associated with plasma metabolites. All 60 406 species had at least one association with a plasma metabolite and there were 2500 associations 407 (1478 positive and 1022 negative) between CACS-associated species and metabolites in total 408 (Table S8). Based on their strongest associations with metabolites the species clustered in 409 410 distinct groups, with one group containing species commonly found in the oral microbiome<sup>24</sup> (e.g., all CACS-associated Streptococcus spp., R. mucilaginosa, Bifidobacterium dentium, and 411 Ligilactobacillus salivarius). Amongst others, this group was negatively associated with a set 412 of uncharacterized molecules, and with indole propionate and positively associated with 413 secondary bile acids and imidazole propionate. The remaining species were dominated by 414 Eubacteriales sp., and included both CACS-positive and negatively associated species and had 415 an inverse metabolic pattern compared to the oral microbiome set, with the exception of 416 tobacco-related metabolites, which were positively associated with CACS-positively 417 418 associated species and negatively associated with CACS-negatively associated species (Figure **S7**). 419

## 420 Oral Species in the Gut Microbiota are Associated with Markers of Systemic 421 Inflammation and Infection

We assessed associations between CACS-associated species and plasma hsCRP (n=8117) and 422 blood counts of leukocytes (n=8098), and neutrophils (n=8092) in linear mixed models. Of 54 423 species positively associated with CACS, 13 were also positively associated with hsCRP, 10 424 with leukocyte counts, and 11 with neutrophil counts (P < 0.05). Species associated with all 425 three markers were dominated by species common in the oral microbiome<sup>24</sup> including the 426 streptococci species most strongly associated with CACS: S. anginosus, S. oralis subsp. oralis, 427 428 and S. parasanguinis. Among the 13 species negatively associated with CACS, 6 were negatively associated with hsCRP, 6 with leukocyte counts, and 5 with neutrophil counts 429 (Figure 5). 430

## 431 CACS-Associated Species from Fecal Samples Correlate with Corresponding Species in 432 Saliva

Several of the CACS-associated species are normally considered as oral species. <sup>24</sup> We 433 therefore investigated the correlation between the abundance of CACS-associated species in 434 the fecal and saliva samples from the 435 participants in MODS (Table S9) who underwent a 435 thorough dental examination within 4 to 12 months after fecal sampling in the MOS. Six of the 436 CACS-associated species were identified in the saliva samples, of which five (S. anginosus, 437 S. parasanguinis, S. gordonii, R. mucilaginosa, and B. dentium) were positively associated 438 with the abundance of the corresponding species in the fecal sample (rho=0.15-0.46), while 439 S. oralis subsp. oralis was not (Table S10). In up to 639 participants from MODS, three species 440 441 (S. anginosus, S. parasanguinis, and R. mucilaginosa) were positively associated with both caries and filled surfaces, and three (S. anginosus, S. gordonii and B. dentium) with gingivitis 442 (Table S11). 443

#### 444 **DISCUSSION**

Gut bacteria have been proposed to affect the development and progression of atherosclerosis 445 through infections local or distal to the atherosclerotic plaque or through production of 446 atherogenic metabolites.<sup>2</sup> The association of gut microbiota with coronary atherosclerosis has 447 previously been studied only in symptomatic patients, who are often under treatment, resulting 448 in high risk of bias as medication may result in large shifts of the composition. Here, detailed 449 image-based measurements of coronary artery atherosclerosis and deep characterization of the 450 gut microbiome by shotgun metagenomics of individuals without earlier cardiovascular disease 451 452 in the large population-based SCAPIS cohort were used to identify 64 species associated with CACS independent of risk factors. Several of these species were associated with circulating 453 markers of inflammation and infection, and with the corresponding bacteria species in saliva 454 samples, which were in turn associated with worse oral health. Thus, studies are merited to 455 continue to investigate the role of these 64 species in atherogenesis. 456

The Streptococcus genus was associated with CACS, consistent with observations in 457 previous case-control studies of symptomatic atherosclerotic cardiovascular disease. 6,7,25 458 Specifically, S. anginosus, S. oralis subsp. oralis, S. parasanguinis, S. gordonii, and 459 S. agalactiae were associated with coronary atherosclerosis. Current knowledge of the 460 involvement of these bacteria in cardiovascular pathologies is summarized in Table S12. These 461 species all belong to the VGS,  $^{26}$  except for *S. agalactiae* (a  $\beta$ -hemolytic non-VGS). VGS can 462 enter the bloodstream through mucosal barrier injuries from daily dental care activities and 463 dental procedures, and could also pass the gut barrier when injured.<sup>27</sup> VGS can infect the valves 464 and the coronary vessels, accounting for 20% of infective endocarditis cases. <sup>4,9,28</sup> VGS species 465 initiate and contribute to biofilm formations, which enhance bacterial survival and have been 466 found in atherosclerotic lesions with unclear significance.<sup>29</sup> Moreover, in model systems, VGS 467 can invade human aortic endothelial cells and stimulate atherosclerosis-related pro-468

inflammatory cytokines. <sup>30</sup> Animal studies suggest a causal link between *Streptococcus* spp.
and atherogenesis. <sup>31,32</sup> In our study, the abundance of CACS-associated *Streptococcus* spp. in
the gut associated strongly and positively with hsCRP, leukocytosis, and neutrophilia, which
could have been triggered by low-grade bacteremia.

The abundance of CACS-associated species might be reduced by antimicrobial treatment. 473 However, clinical trials showed that anti-infective therapies, targeted at chlamydial 474 colonization of the coronary plaques, seemed harmful in patients with established coronary 475 heart disease. <sup>33</sup> In the CLARICOR study, mortality was increased in patients with stable 476 coronary artery disease treated with clarithromycin. <sup>34</sup> Possible explanations to why these 477 antibiotics were ineffective in reducing coronary events include resistance to antibiotics due to 478 biofilm formation, <sup>35</sup> recolonization after antibiotic treatment, the need for treatment earlier in 479 atherosclerosis process, or simply that these bacteria are not causal to atherosclerosis. In the 480 current study, participants with low abundance of CACS-associated Streptococcus spp. were 481 not more exposed to antibiotics over the past 12 months than those with higher abundance. We 482 also found that the abundance of *Streptococcus* spp. was associated with coronary artery 483 calcification even after exclusion of participants treated with antibiotics. 484

We assessed the association of the CACS-associated species with other measures of 485 coronary atherosclerosis from the CCTA as well as with carotid atherosclerosis measured by 486 ultrasound. In general, we found high agreement of associations of species with CACS, 487 modified Duke index, any atherosclerosis, and SIS. However, the associations with having an 488 occlusion >50% of at least one vessel were weaker, perhaps because this was a rather rare 489 phenotype in our cohort, with low power. Likewise, only a few of the species were associated 490 with carotid plaque, perhaps because the measurement of carotid plaque was not very detailed 491 or because associations differ in different vascular beds. 492

The gut microbiota composition might also contribute to atherogenesis through alteration 493 of the host metabolism. In the current study, all CACS-associated species were associated with 494 at least one plasma metabolite and clustered in distinct groups based on their associations with 495 the metabolome. One group, which contained all the species commonly found in saliva, was 496 positively associated with several microbiota-derived metabolites such as primary and 497 secondary bile acids, and with omeprazole and metformin. Furthermore this group was 498 negatively associated with the microbially-derived tryptophan metabolite indole propionate, a 499 metabolite which has been found inversely associated with atherosclerotic coronary disease in 500 humans and reduced progression of atherosclerosis in mice.<sup>36</sup> Bacteria of this group were also 501 found positively associated with imidazole propionate, a microbially-derived metabolite from 502 histidine, reported to impair glucose metabolism. <sup>37</sup> Several tobacco metabolites, i.e. 3-503 hydroxycotinine glucuronide, cotinine N-oxide and norcotinine, were positively associated 504 with species positively associated with CACS and negatively associated with species 505 negatively associated with CACS. Together, these findings suggest an interplay between 506 CACS-associated species and microbial metabolite production, drug intake and smoking 507 behavior. 508

Another aspect of the microbiome is the functional metabolic potential, which can be 509 summarized into metabolic modules based on known functions of bacterial genes. <sup>20</sup> We found 510 eleven modules positively associated with CACS, with the strongest associations noted for 511 512 dissimilatory nitrate reduction and anaerobic fatty acid beta-oxidation. Dietary nitrate is absorbed in the intestines and excreted back into the gastrointestinal tract by the salivary glands 513 at high concentrations, forming the so-called entero-salivary circulation of nitrate. Denitrifying 514 oral bacteria are important for converting nitrate  $(NO_3^-)$  into nitrite  $(NO_2^-)$ , which can be 515 further converted into nitric oxide (NO) in the acidic pH of the stomach. The generation of NO 516 contributes to the gastric protection by increasing blood flow and mucus thickness. <sup>38</sup> The 517

nitrate and nitrite that is not converted to NO in the stomach is absorbed into the bloodstream 518 and tissues, where they might have act as reservoir for NO, which appear to be important for 519 vasodilation under hypoxia<sup>39</sup> and modulation of mitochondrial respiration. <sup>40</sup> However, the 520 dissimilatory nitrate reduction pathway converts nitrate to ammonia, and having an increased 521 activity of this pathway in the colon could potentially inhibit the potential positive 522 cardiovascular effects of nitrate. We found that genes related to anaerobic fermentation of fatty 523 524 acids were associated with CACS. Such genes are rather uncommon in the gut microbiota and the genetic background of oxidation of fatty acids under anaerobic conditions is not well 525 526 characterized. We found an association of five amino acid breakdown modules with CACS. This could be driven by differences in diet not captured by our covariates. 527

Our study has some limitations. First, although our cohort is at least seven times larger than 528 those analyzed previously, few participants had high levels of subclinical atherosclerosis, 529 reducing statistical power. Second, microbial composition can vary extensively throughout the 530 gastrointestinal tract. Fecal samples contain microbial populations from the distal colon, and 531 less so from other sites such as the small intestine. Therefore, we could not identify associations 532 of species that are not well represented in fecal samples. Third, our study does not take into 533 consideration the different interactions among bacterial species such as synergistic effects in 534 the relationship with coronary atherosclerosis. Fourth, the cross-sectional study design limits 535 causal inference. Finally, our data on antibiotic treatment does not capture antibiotics provided 536 537 in inpatient care; however, in this age group, we do not expect a large number of hospitaltreated patients. In future studies, different causal inference methods should be used to 538 determine whether the identified species are causally related to atherosclerosis development. 539

540 In conclusion, by combining data from a large population-based cohort study and imaging 541 to evaluate subclinical coronary atherosclerosis, we found that the abundance of several species 542 in the gut were associated with coronary atherosclerosis, biomarkers of inflammation, and their

oral counterparts. If causal, these species might contribute to atherogenesis by direct infection
or by altering host metabolism. Future studies will show whether these species can be used as
potential biomarkers or treatment targets.

546

#### 547 Sources of Funding

The main financial support for the study was from the European Research Council [ERC-2018-548 STG-801965 (T.F.), ERC-CoG-2014-649021 (M.O.-M.), and ERC-STG-2015-679242 549 (J.G.S.)]. Funding was also provided by the Swedish Research Council [VR, 2019-01471 550 551 (T.F.), 2018-02784 (M.O.-M.), 2018-02837 (M.O.-M.), 2019-01015 (J.Ä.), 2020-00243 (J.Ä.), 2019-01236 (G.E.), 2017-02554 (J.G.S.), 2022-01460 (SA) and EXODIAB 2009-1039 (M.O.-552 M.)]; the Swedish Heart-Lung Foundation [Hjärt-Lungfonden 20190505 (T.F.), 20200711 553 (M.O.-M.), 20180343 (J.Ä.), 2019-0526 (J.G.S.), 20200173 (G.E.)]; the A.L.F. governmental 554 grant [2018-0148 (M.O.-M.)]; the Novo Nordisk Foundation [NNF20OC0063886 (M.O.-M.)]; 555 the Swedish Diabetes Foundation [(DIA 2018-375 (M.O.-M.)]; the Swedish Foundation for 556 Strategic Research [LUDC-IRC 15-0067 (M.O.-M.)]; Formas [2020-00989 (S.A.)]; Göran 557 Gustafsson Foundation [2016 (T.F.)]; and Axel and Signe Lagerman's Foundation (T.F.). 558

The Swedish CArdioPulmonary bioImage Study (SCAPIS) was funded mainly by the Swedish Heart-Lung Foundation. The study was also funded by the Knut and Alice Wallenberg Foundation, the Swedish Research Council and VINNOVA (Sweden's innovation agency), the University of Gothenburg and Sahlgrenska University Hospital, Karolinska Institutet and Stockholm County Council, Linköping University and University Hospital, Lund University and Skåne University Hospital, Umeå University and University Hospital, and Uppsala University and University Hospital.

The Malmö Offspring Dental Study (MODS) was funded mainly by Oral Health Related
Research by Region Skåne (OFRS 422361, OFRS 512951, OFRS 567711, OFRS 655561,

OFRS 752071, OFRS 853031, OFRS 931171, and OFRS968144). The Malmö Offspring Study
(MOS) was funded by the Swedish Research Council [VR, 521-2013-2756 (P.M.N.)], the
Swedish Heart and Lung Foundation [Hjärt-Lungfonden 20150427 (P.M.N.)], and by A.L.F.
from the local Region Skåne County Council (P.M.N.). In addition, funding was obtained from
Ernhold Lundströms Stiftelse (L.B.).

The computations and data handling were enabled by resources in project sens2019512 provided by the National Academic Infrastructure for Supercomputing in Sweden (NAISS) and the Swedish National Infrastructure for Computing (SNIC) at Uppsala Multidisciplinary Center for Advanced Computational Science (UPPMAX) partially funded by the Swedish Research Council through grant agreements no. 2022-06725 and no. 2018-05973.

#### 578 Disclosures

579 The authors declare the following competing interests: Ms Pita, Ms Nielsen, Drs Eklund, Holm,

and Nielsen are employees of Clinical Microbiomics A/S, where samples were processed and

581 DNA extraction and estimations of relative abundance of the metagenomics species were done.

582 Dr Ärnlöv has received lecture fees from Novartis and AstraZeneca and has served on advisory

boards for AstraZeneca and Boerhinger Ingelheim, all unrelated to the present paper. Dr
Nilsson has received lecture fees from Novartis, Novo Nordisk, Amgen, and Boerhinger

585 Ingelheim. The other authors declare no competing interests.

#### 586 Supplemental Material

- 587 Supplemental Methods
- 588 Tables S1-S12
- 589 Figures S1-S7

#### **Table 1** Descriptive characteristics of participants in the SCAPIS study with metagenomics

#### 591 data and no previous CVD event

	Malmö	Uppsala	Observations
N	4541	4432	
Age (years)*	57.3 (4.3)	57.6 (4.4)	8973
Female, n (%)	2480 (54.6%)	2336 (52.7%)	8973
CACS <sup>†‡</sup>	0.0 [0.0;27.0]	0.0 [0.0;15.0]	8973
Clinical CACS, n (%) <sup>‡</sup> :			8973
0	2574 (56.7%)	2781 (62.7%)	
1-100	1379 (30.4%)	1187 (26.8%)	
101-400	398 (8.8%)	319 (7.2%)	
>400	190 (4.2%)	145 (3.3%)	
Any atherosclerosis, n (%)	1781 (45.9%)	1650 (40.8%)	7924
Stenosis > 50%, n (%)	224 (5.8%)	263 (6.5%)	7924
Modified Duke index >1, n (%)	1104 (28.4%)	968 (24.0%)	7924
Segment involvement score >4, n (%)	379 (9.8%)	283 (7.0%)	7924
Carotid arteries with identified plaques, n (%):			8955
None	1862 (41.1%)	1959 (44.2%)	
Unilateral	1388 (30.7%)	1391 (31.4%)	
Bilateral	1275 (28.2%)	1080 (24.4%)	
Country of birth, n (%):			8973
Scandinavia	3575 (78.7%)	4001 (90.3%)	
Non-Scandinavian Europe	629 (13.9%)	165 (3.7%)	
Asia	237 (5.2%)	170 (3.8%)	
Other	100 (2.2%)	96 (2.2%)	
Smoking, n (%):			8638
Never smoker	1948 (44.0%)	2469 (58.6%)	
Former smoker	1681 (38.0%)	1351 (32.1%)	
Current smoker	795 (18.0%)	394 (9.3%)	

Physical activity in leisure time, n (%):			8464
Sedentary	594 (13.8%)	425 (10.2%)	
Moderate exercise	2107 (48.9%)	1873 (45.1%)	
Moderate but regular exercise	1114 (25.8%)	1357 (32.7%)	
Regular exercise and training	498 (11.5%)	496 (11.9%)	
Triglycerides, mmol/L <sup>†</sup>	1.1 [0.8;1.5]	1.1 [0.8;1.5]	8955
LDL cholesterol, mmol/L *‡	3.6 (0.9)	3.6 (0.9)	8951
HDL cholesterol, mmol/L <sup>†‡</sup>	1.6 [1.3;2.0]	1.4 [1.2;1.7]	8952
Total cholesterol, mmol/L *	5.5 (1.0)	5.7 (1.0)	8954
Systolic blood pressure, mmHg* <sup>‡</sup>	122.3 (16.4)	124.9 (15.9)	8969
Diastolic blood pressure, mmHg* <sup>‡</sup>	74.7 (9.7)	76.9 (9.8)	8969
Body mass index, kg/m <sup>2‡</sup>	27.2 (4.6)	27.0 (4.4)	8973
hsCRP, mmol/L <sup>†‡</sup>	1.2 [0.6;2.4]	1.2 [0.6;2.3]	8955
Neutrophil count, 10 <sup>9</sup> /L <sup>†</sup>	3.0 [2.4;3.8]	2.8 [2.3;3.5]	8930
Leukocyte count,10 <sup>9</sup> /L <sup>†</sup>	5.6 [4.7;6.7]	5.3 [4.6;6.3]	8937
Total energy intake, kcal/day <sup>†</sup>	1579.4	1613.0	8845
	[1221.1;2066.8]	[1270.7;2048.3]	
Carbohydrate intake, E% <sup>†‡</sup>	44.6 [39.9;49.0]	44.5 [40.3;48.5]	8845
Protein intake, E% <sup>†‡</sup>	16.8 [14.7;19.0]	17.0 [15.3;18.9]	8845
Fat intake, E% <sup>†‡</sup>	36.7 [32.7;40.6]	36.5 [32.7;40.3]	8845
Fiber intake, g/1000kcal <sup>†</sup>	11.7 [9.0;14.6]	11.8 [9.3;14.5]	8845
Diabetes, n (%)	198 (4.5%)	171 (4.1%)	8552
Inflammatory bowel disease, n (%)	43 (1.0%)	52 (1.2%)	8499
Medication for dyslipidemia, n (%)	292 (6.7%)	274 (6.5%)	8550
Medication for high blood pressure, n (%)	834 (19.2%)	764 (18.2%)	8544
Medication for diabetes, n (%)	165 (3.8%)	140 (3.3%)	8544
Proton-pump inhibitor, n (%)	161 (4.6%)	122 (2.8%)	7906
Past year narrow spectrum antibiotics treatment, n (%)	579 (12.8%)	550 (12.4%)	8973

Past year broad spectrum antibiotics treatment, n	505 (11.1%)	400 (9.0%)	8973
(%)			

- 592 \*Mean (standard deviation)
- <sup>†</sup>Median [interquartile range]
- <sup>594</sup> <sup>‡</sup>CACS indicates coronary artery calcium score; LDL, low-density lipoprotein; HDL, high-
- density lipoprotein; hsCRP, high-sensitivity C-reactive protein, E%, percentage of total
- 596 energy intake.

#### 597 Figures



----

599







#### 602 Figure 2. Association of alpha and beta diversity with CACS.

The association of alpha diversity (a) with coronary atherosclerosis was assessed by fitting 603 linear mixed models with CACS as the outcome and the alpha diversity indices as the exposure. 604 605 The basic model (n=8972) was adjusted for age, sex, country of birth, and metagenomics extraction plate as fixed effects and family relatedness as random effect. The main model 606 (n=8118) was further adjusted for, smoking, physical activity, energy-adjusted intake of 607 608 carbohydrate, protein, and fiber, systolic blood pressure (SBP), and diastolic blood pressure (DBP), total cholesterol, HDL and LDL cholesterol, triglycerides, BMI, diabetes, and self-609 reported medication for dyslipidemia, hypertension, and diabetes as fixed effects. For beta 610 diversity (b), a distance-based multivariate analysis of variance of CACS as the independent 611 variable was applied and the same fixed effect adjustments were made without the random 612 effect adjustment. In the basic (n=8757) and the full model (n=7921) one participants for each 613 family relatedness cluster was removed. Box plots represent the Bray-Curtis dissimilarity 614 between participants with CACS=0 and the other CACS groups. For the CACS=0, the boxplot 615 616 represents the within group dissimilarity.



Figure 3. Phylum-level taxonomical profiling of the fecal and saliva samples across the





620

#### 621 Figure 4. Cladogram of species investigated in the study.

622 Circles represent metagenomic species annotated to the lowest taxonomic level. Dots indicate 623 the species positively (red) and negatively (blue) associated with CACS in the main model 624 (false discovery rate <5%). A: *Actinobacteria*; P: *Proteobacteria*; B: *Bacteroides*; F: 625 *Firmicutes*. The following unclassified non-CACS-associated metagenomics species were 626 collapsed: \*99 species with lowest annotation to the order *Bacteroidales*, <sup>†</sup>95 species with 627 lowest annotation to phylum *Firmicutes*, <sup>‡</sup>163 species with lowest annotation to the class 628 *Clostridia*, and <sup>§</sup>651 species with lowest annotation to the order *Eubacteriales*.



629

Figure 5. Associations between CACS-related gut species and alternate measurements of 630 atherosclerosis and markers of inflammation and infection. Heatmap showing the 631 associations of the 64 coronary artery calcium score (CACS)-associated species (False 632 Discovery Rate (FDR) q-value<0.05) with CACS, other coronary computed tomography 633 angiography atherosclerosis traits, carotid plaque, and inflammation biomarkers. Associations 634 with CACS and with inflammatory markers hsCRP (high-sensitivity C-reactive protein), 635 neutrophil and leukocyte counts are presented as linear regression coefficients after adjustment 636 for the main model covariates (age, sex, country of birth, metagenomics extraction plate, 637 smoking, physical activity, energy-adjusted carbohydrate, protein and fiber intake, systolic and 638

639	diastolic blood pressure, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and
640	total cholesterol, triglycerides, body mass index (BMI), diabetes, and self-reported medication
641	for dyslipidemia, hypertension, and diabetes as fixed effects and first-degree family relatedness
642	as a random effect). Associations with atherosclerosis traits (i.e., modified Duke index,
643	segment involvement score (SIS), any atherosclerosis, and $\geq$ 50% stenosis) and presence of
644	carotid plaques are presented as odds ratio (OR) after adjustment for main model covariates.
645	Associations with FDR q-value $< 0.05$ are marked with two asterisks (**) and those with P $< 0.05$
646	are marked with one asterisk (*).

#### 647 **REFERENCES**

648

- 649 1. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, 650 Beaton AZ, Benjamin EJ, Benziger CP, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update From the GBD 2019 Study. Journal of the American College 651 652 of Cardiology. 2020;76:2982-3021. doi: https://doi.org/10.1016/j.jacc.2020.11.010 2. Jonsson AL, Bäckhed F. Role of gut microbiota in atherosclerosis. Nat Rev Cardiol. 653 654 2017;14:79-87. doi: 10.1038/nrcardio.2016.183 655 3. Chakaroun RM, Olsson LM, Backhed F. The potential of tailoring the gut microbiome to 656 prevent and treat cardiometabolic disease. Nat Rev Cardiol. 2023;20:217-235. doi: 657 10.1038/s41569-022-00771-0 658 4. Ott SJ, Mokhtari NEE, Musfeldt M, Hellmig S, Freitag S, Rehman A, Kühbacher T, Nikolaus S, 659 Namsolleck P, Blaut M, et al. Detection of diverse bacterial signatures in atherosclerotic 660 lesions of patients with coronary heart disease. Circulation. 2006;113:929-937. doi: 661 10.1161/CIRCULATIONAHA.105.579979 662 5. Fromentin S, Forslund SK, Chechi K, Aron-Wisnewsky J, Chakaroun R, Nielsen T, Tremaroli V, 663 Ji B, Prifti E, Myridakis A, et al. Microbiome and metabolome features of the cardiometabolic 664 disease spectrum. Nature Medicine 2022. 2022;37:1-12. doi: 10.1038/s41591-022-01688-4 Jie Z, Xia H, Zhong SL, Feng Q, Li S, Liang S, Zhong H, Liu Z, Gao Y, Zhao H, et al. The gut 665 6. microbiome in atherosclerotic cardiovascular disease. Nature Communications. 2017;8:845. 666 667 doi: 10.1038/s41467-017-00900-1 668 7. Liu H, Chen X, Hu X, Niu H, Tian R, Wang H, Pang H, Jiang L, Qiu B, Chen X, et al. Alterations in 669 the gut microbiome and metabolism with coronary artery disease severity. *Microbiome*. 670 2019;7:68. doi: 10.1186/s40168-019-0683-9 671 8. Schmidt TS, Hayward MR, Coelho LP, Li SS, Costea PI, Voigt AY, Wirbel J, Maistrenko OM, 672 Alves RJ, Bergsten E, et al. Extensive transmission of microbes along the gastrointestinal 673 tract. *Elife*. 2019;8. doi: 10.7554/eLife.42693 674 9. Koren O, Spor A, Felin J, Fåk F, Stombaugh J, Tremaroli V, Behre CJ, Knight R, Fagerberg B, 675 Ley RE, et al. Human oral, gut, and plaque microbiota in patients with atherosclerosis. 676 Proceedings of the National Academy of Sciences of the United States of America. 677 2011;108:4592-4598. doi: 10.1073/pnas.1011383107 678 10. Jönsson D, Orho-Melander M, Demmer RT, Engström G, Melander O, Klinge B, Nilsson PM. 679 Periodontal disease is associated with carotid plaque area: the Malmö Offspring Dental 680 Study (MODS). Journal of Internal Medicine. 2020;287:301-309. doi: 10.1111/JOIM.12998 681 Ryden L, Buhlin K, Ekstrand E, de Faire U, Gustafsson A, Holmer J, Kjellstrom B, Lindahl B, 11. 682 Norhammar A, Nygren A, et al. Periodontitis Increases the Risk of a First Myocardial 683 Infarction: A Report From the PAROKRANK Study. Circulation. 2016;133:576-583. doi: 684 10.1161/CIRCULATIONAHA.115.020324 Tonetti MS, D'Aiuto F, Nibali L, Donald A, Storry C, Parkar M, Suvan J, Hingorani AD, Vallance 685 12. 686 P, Deanfield J. Treatment of periodontitis and endothelial function. N Engl J Med. 687 2007;356:911-920. doi: 10.1056/NEJMoa063186 Bergström G, Berglund G, Blomberg A, Brandberg J, Engström G, Engvall J, Eriksson M, Faire 688 13. Ud, Flinck A, Hansson MG, et al. The Swedish CArdioPulmonary BioImage Study: Objectives 689 and design. Journal of Internal Medicine. 2015;278:645-659. doi: 10.1111/joim.12384 690 691 14. Brunkwall L, Jönsson D, Ericson U, Hellstrand S, Kennbäck C, Östling G, Jujic A, Melander O, 692 Engström G, Nilsson J, et al. The Malmö Offspring Study (MOS): design, methods and first results. European Journal of Epidemiology. 2021;36:103-116. doi: 10.1007/s10654-020-693 694 00695-4 695 15. Bergström G, Persson M, Adiels M, Björnson E, Bonander C, Ahlström H, Alfredsson J,
- 696 Angerås O, Berglund G, Blomberg A, et al. Prevalence of Subclinical Coronary Artery

697		Atherosclerosis in the General Population. Circulation. 2021;144:916-929. doi:
698		10.1161/CIRCULATIONAHA.121.055340
699	16.	Ohnesorge B, Flohr T, Fischbach R, Kopp AF, Knez A, Schroder S, Schopf UJ, Crispin A, Klotz E,
700		Reiser MF, et al. Reproducibility of coronary calcium quantification in repeat examinations
701		with retrospectively ECG-gated multisection spiral CT. <i>Eur Radiol</i> . 2002;12:1532-1540. doi:
702		10.1007/s00330-002-1394-2
703	17.	Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, Csiba L, Desvarieux
704		M, Ebrahim S, Hernandez RH, et al. Mannheim Carotid Intima-Media Thickness and Plaque
705		Consensus (2004–2006–2011): An Update on Behalf of the Advisory Board of the 3rd and 4th
706		Watching the Risk Symposium 13th and 15th European Stroke Conferences, Mannheim,
707		Germany, 2004, and Brussels, Belgium, 2006. Cerebrovascular diseases (Basel, Switzerland).
708		2012;34:290. doi: 10.1159/000343145
709	18.	Nielsen HB, Almeida M, Juncker AS, Rasmussen S, Li J, Sunagawa S, Plichta DR, Gautier L,
710		Pedersen AG, Chatelier EL, et al. Identification and assembly of genomes and genetic
711		elements in complex metagenomic samples without using reference genomes. <i>Nature</i>
712		Biotechnology. 2014:32:822-828. doi: 10.1038/nbt.2939
713	19.	O'Leary NA, Wright MW, Brister JR, Ciufo S, Haddad D, McVeigh R, Raiput B, Robbertse B,
714		Smith-White B. Ako-Adiei D. et al. Reference sequence (RefSeq) database at NCBI: current
715		status, taxonomic expansion, and functional annotation. <i>Nucleic acids research</i>
716		2016:44:D733-D745, doi: 10.1093/NAR/GKV1189
717	20	Vieira-Silva S, Falony G, Darzi Y, Lima-Mendez G, Garcia Yunta R, Okuda S, Vandenutte D
718	20.	Valles-Colomer M. Hildebrand F. Chaffron S. et al. Species-function relationships shape
719		ecological properties of the human gut microbiome. <i>Nature Microbiology</i> 2016:1:16088
720		doi: 10.1038/nmicrohiol.2016.88
721	21	Dekkers KE Savols-Baixeras S Baldanzi G Nowak C Hammar II Nguyen D Varotsis G
722	21.	Brunkwall I. Nielsen N. Eklund AC. et al. An online atlas of human plasma metabolite
722		signatures of gut microbiome composition. <i>Nature Communications</i> 2022:13:5370. doi:
723		10 1038/c/1/67-022-33050-0
724	22	Benjamini V. Hochberg V. Controlling the False Discovery Rate: A Practical and Powerful
725	22.	Annroach to Multiple Testing Journal of the Royal Statistical Society Series B
720		(Methodological) 1995:57:289-300 doi: https://doi.org/10.1111/j.2517-
728		6161 1995 th02031 v
720	22	Korotkovich G. Sukhov V. Budin N. Shnak B. Artvomov MN. Sargushichov A. East gone set
729	23.	enrichment analysis bioRxiv 2021:060012 doi: 10.1101/060012
730	24	Casolli E. Eabhri C. D'Accolti M. Soffritti I. Passi C. Mazzasano S. Eranchi M. Dofining the oral
751	24.	misrobiome by whole genome sequencing and registering analysis; the complexity of the
732		halthy picture <i>BMC Microbiol</i> 2020:20:120 doi: 10.1126/c12266.020.01201.y
755	25	Liu S. Zhao M. Liu X. Chang L. Mataganamic analysis of the gut microbiomo in atherosclerosis
734	25.	Liu S, Zildo W, Liu X, Cheng L. Metagenolinic analysis of the gut microbioline in atheroscierosis
755		hours and approximate the second signatures and potential therapeutic target. FASED
730	26	Journal. 2020;34:14100-14181. doi: 10.1090/1J.202000022K
737	20.	Doern CD, Burnham C-AD. It's Not Easy Being Green. the Vindans Group Streptococci, with a
738		Focus on Pediatric Clinical Manifestations. <i>Journal of Clinical Microbiology</i> . 2010;48:3829.
739	27	dol: 10.1128/JCM.01563-10
740	27.	Locknart PB, Brennan WI, Sasser HC, Fox PC, Paster BJ, Banrani-Mougeot FK. Bacteremia
741		associated with toothbrushing and dental extraction. <i>Circulation</i> . 2008;117:3118-3125. doi:
742	20	10.1101/CIKCULATIONAHA.10/./58524
743	28.	vienman JA, Smith BJ, Nanjappa S, LI SK, Perez CO, Fernandes CR. Chapter 3 - Microbiology
744	20	or endocarditis. In: Kilic A, ed. <i>Injective Endocarditis</i> . Academic Press; 2022:43-59.
745	29.	Lanter BB, Davies DG. Propionipacterium acnes recovered from atheroscierotic numan
/46		carotio arteries undergoes plotilm dispersion and releases lipolytic and proteolytic enzymes

747 748		in response to norepinephrine challenge In vitro. <i>Infection and Immunity</i> . 2015;83:3960- 3971. doi: 10.1128/IAI.00510-15/SUPPL FILE/7II999091420SO1.PDF
749	30.	Nagata E, Toledo AD, Oho T. Invasion of human aortic endothelial cells by oral viridans group
750		streptococci and induction of inflammatory cytokine production. <i>Molecular Oral</i>
751	24	Microbiology. 2011;26:78-88. doi: 10.1111/J.2041-1014.2010.00597.X
752	31.	Hasnizume-Takizawa T, Yamaguchi Y, Kobayashi R, Shinozaki-Kuwanara N, Saito M, Kurita-
753		Ochial I. Oral challenge with <i>Streptococcus sanguinis</i> induces aortic inflammation and
754 755		accelerates atheroscierosis in spontaneously hyperlipidemic mice. <i>Biochemical ana</i>
755 756	22	Biophysical Research Communications. 2019;520:507-513. doi: 10.1016/J.00rc.2019.10.057
750	32.	Resavaiu L, Lucas AR, Verma RK, Liu L, Dai E, Sampson E, Proguiske-Fox A. Increased
757		Research 2012:01:255 260 doi: 10.1177/0022024511425101
750	22	Acseurch. 2012, 51.255-200. doi: 10.1177/0022054511455101
759	55.	beart disease. Cochrane Database Syst Rev. 2019
760	3/	lespersen CM. Randomised placebo controlled multicentre trial to assess short term
762	54.	clarithromycin for nations with stable coronary heart disease: CLARICOR trial <i>British</i>
762		Medical Journal 2006:332:22-24 doi: 10.1136/bmi 38666.653600.55
767	35	Sharma D. Misha I. Khan All. Antibiotics versus biofilm: an emerging battleground in
765	55.	microhial communities Antimicrohial Resistance & Infection Control 2019:8:76 doi:
766		10 1186/c13756-019-0533-3
767	36	Xue H. Chen X. Yu C. Deng Y. Zhang Y. Chen S. Chen X. Chen K. Yang Y. Ling W. Gut
768	50.	Microbially Produced Indole-3-Propionic Acid Inhibits Atherosclerosis by Promoting Reverse
769		Cholesterol Transport and Its Deficiency Is Causally Related to Atherosclerotic Cardiovascular
770		Disease. <i>Circ Res</i> . 2022:131:404-420. doi: 10.1161/CIRCRESAHA.122.321253
771	37.	Koh A. Molinaro A. Stahlman M. Khan MT. Schmidt C. Manneras-Holm L. Wu H. Carreras A.
772		Jeong H. Olofsson LE. et al. Microbially Produced Imidazole Propionate Impairs Insulin
773		Signaling through mTORC1. <i>Cell</i> . 2018:175:947-961 e917. doi: 10.1016/i.cell.2018.09.055
774	38.	Bjorne HH, Petersson J, Phillipson M, Weitzberg E, Holm L, Lundberg JO. Nitrite in saliva
775		increases gastric mucosal blood flow and mucus thickness. J Clin Invest. 2004;113:106-114.
776		doi: 10.1172/JCl19019
777	39.	Cosby K, Partovi KS, Crawford JH, Patel RP, Reiter CD, Martyr S, Yang BK, Waclawiw MA,
778		Zalos G, Xu X, et al. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the
779		human circulation. Nat Med. 2003;9:1498-1505. doi: 10.1038/nm954
780	40.	Shiva S, Huang Z, Grubina R, Sun J, Ringwood LA, MacArthur PH, Xu X, Murphy E, Darley-
781		Usmar VM, Gladwin MT. Deoxymyoglobin is a nitrite reductase that generates nitric oxide
782		and regulates mitochondrial respiration. Circ Res. 2007;100:654-661. doi:
783		10.1161/01.RES.0000260171.52224.6b
784	41.	Christensen SE, Moller E, Bonn SE, Ploner A, Wright A, Sjolander A, Balter O, Lissner L, Balter
785		K. Two new meal- and web-based interactive food frequency questionnaires: validation of
786		energy and macronutrient intake. J Med Internet Res. 2013;15:e109. doi: 10.2196/jmir.2458
787	42.	Silness J, Loe H. Periodontal Disease in Pregnancy. Ii. Correlation between Oral Hygiene and
788		Periodontal Condtion. Acta Odontol Scand. 1964;22:121-135. doi:
789		10.3109/00016356408993968
790	43.	Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. <i>Nature Methods 2012</i>
791		9:4. 2012;9:357-359. doi: 10.1038/nmeth.1923
792	44.	Pasolli E, Asnicar F, Manara S, Zolfo M, Karcher N, Armanini F, Beghini F, Manghi P, Tett A,
793		Ghensi P, et al. Extensive Unexplored Human Microbiome Diversity Revealed by Over
/94 705		150,000 Genomes from Metagenomes Spanning Age, Geography, and Lifestyle. Cell.
795 706	45	2019;1/0:049-062.0620.001:10.1016/J.COII.2019.01.001
796 797	45.	fast and scalable metagenome assembler driven by advanced methodologies and

798		community practices. Methods (San Diego, Calif). 2016;102:3-11. doi:
799		10.1016/J.YMETH.2016.02.020
800	46.	Steinegger M, Söding J. Clustering huge protein sequence sets in linear time. Nature
801		communications. 2018;9:2542. doi: 10.1038/S41467-018-04964-5
802	47.	Huerta-Cepas J, Szklarczyk D, Heller D, Hernández-Plaza A, Forslund SK, Cook H, Mende DR,
803		Letunic I, Rattei T, Jensen LJ, et al. eggNOG 5.0: a hierarchical, functionally and
804		phylogenetically annotated orthology resource based on 5090 organisms and 2502 viruses.
805		Nucleic Acids Research. 2019;47:D309-D314. doi: 10.1093/NAR/GKY1085
806	48.	Cantalapiedra CP, Hernández-Plaza A, Letunic I, Bork P, Huerta-Cepas J. eggNOG-mapper v2:
807		Functional Annotation, Orthology Assignments, and Domain Prediction at the Metagenomic
808		Scale. Molecular Biology and Evolution. 2021;38:5825-5829. doi:
809		10.1093/MOLBEV/MSAB293